The authors reply [6]

New England Journal of Medicine

Volumn 354, Issue 25, 2006, Pages 2726-

  Park Wyllie, Laura Y ^a   Shah, Baiju R ^a   Juurlink, David N ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

DRUG MARKETING; DYSGLYCEMIA; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LETTER; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS;

EID: 33745283649     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061105     Document Type: Letter

References (3)

1. Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303-9.
2. Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005;41:1269-76.
3. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005;25:1296-302.